Bayer’s Vividion rising as vital participant in San Diego biotech hub

Leverkusen and San Diego, June 9, 2022 – Bayer AG and its wholly owned San Diego-based subsidiary Vividion Therapeutics, Inc. (Vividion) will spotlight how the 2 corporations have fostered innovation and collaboration by Bayer’s “arm’s size” working mannequin throughout a presentation on the 2022 BIO Worldwide Conference.

Bayer has constructed a robust partnership with Vividion since its acquisition of the biopharmaceutical firm in 2021, deploying an modern enterprise mannequin that permits Vividion to function largely autonomously and independently to develop and advance its novel pipeline and platform applied sciences. 

“Vividion’s arm’s size however related relationship with Bayer has given us a singular and extremely fascinating working mannequin,” stated Jeffrey Hatfield, Chief Govt Officer at Vividion. “The independence has allowed us to maintain our entrepreneurial tradition, quick determination making and concentrate on breakthrough innovation, whereas the connection provides vital technical experience, international attain and the monetary stability of a serious pharmaceutical firm. With all these strengths, we’ve been in a position to speed up progress on our pipeline of novel, beforehand undruggable goal packages this previous yr, and we stay up for the opportunity of delivering a number of packages into the clinic beginning subsequent yr.”

“Our companions thrive when empowered, and our goal is for Vividion to proceed to advance innovation in an entrepreneurial setting centered on affected person advantages and outcomes,” stated Marianne De Backer, MBA, Ph.D., Member of the Govt Committee of the Prescription drugs Division and Head of Technique, Enterprise Improvement & Licensing and Open Innovation at Bayer. “We hearken to our companions’ wants and are versatile in the best way we steer our engagements. Because of this, we’re pursuing modern enterprise fashions with exterior innovators, recognizing that in the present day’s life sciences setting requires adaptive, agile approaches to offers and determination making.” 

By addressing key limitations of standard drug discovery strategies, Vividion’s proprietary chemoproteomic platform expertise permits the corporate to unlock excessive worth, historically undruggable goal biology with precision therapeutics for cancers and immune problems. Lately, Benjamin Cravatt, Professor of Chemistry at The Scripps Analysis Institute and Vividion’s scientific co-founder, obtained the celebrated Wolf Prize in Chemistry for this technologic breakthrough. As essentially the most superior platform of its sort within the {industry}, Vividion provides one other drug discovery engine that may gas its pipeline with first-in-class medicines at an unprecedented velocity to Bayer’s portfolio. 

Vividion is already advancing a number of novel biology, first-in-class packages in direction of the clinic and has greater than a dozen comparable pipeline alternatives rising in early discovery. Combining Bayer’s distinguished historical past and accomplishments in small molecule improvement with Vividion’s industry-leading chemoproteomic platform engine addresses identified limits within the subject of drug discovery to determine small molecules for disease-relevant protein targets historically regarded as undruggable.

With Vividion’s new, state-of-the-art analysis campus in San Diego, Bayer has expanded its operations into this fast-growing life sciences cluster. The corporate is now current in 4 of the most important biotechnology hubs in america – Boston, San Francisco, San Diego and Analysis Triangle Park, NC. 

Particulars of the Bayer and Vividion presentation on the 2022 BIO Conference in San Diego:

“Cultivating innovation post-acquisition: Bayer and Vividion’s arm’s size mannequin” by Marianne De Backer, Ph.D., EVP, Head of Technique, Enterprise Improvement & Licensing and Open Innovation at Bayer, and Jeffrey Hatfield, CEO of Vividion Therapeutics 

· Monday, June 13, 1:00 PM – 2:00 PM (PDT), San Diego Conference Middle, Higher Degree, Session Room 3

https://www.bio.org/events/bio-international-convention/sessions/933729

About Bayer

Bayer is a world enterprise with core competencies within the life science fields of well being care and diet. Its services are designed to assist folks and the planet thrive by supporting efforts to grasp the foremost challenges introduced by a rising and growing older international inhabitants. Bayer is dedicated to driving sustainable improvement and producing a optimistic influence with its companies. On the identical time, the Group goals to extend its incomes energy and create worth by innovation and progress. The Bayer model stands for belief, reliability and high quality all through the world. In fiscal 2021, the Group employed round 100,000 folks and had gross sales of 44.1 billion euros. R&D bills earlier than particular objects amounted to five.3 billion euros. For extra info, go to www.bayer.com.

About Vividion

Vividion Therapeutics, Inc. is a biopharmaceutical firm using novel discovery applied sciences to unlock excessive worth, historically undruggable targets with precision therapeutics for devastating cancers and immune problems. The corporate’s platform has enabled it to determine a whole lot of beforehand unknown useful pockets on well-validated protein targets implicated in a variety of illnesses, whereas concurrently figuring out compounds from its proprietary covalent chemistry library that work together in a extremely selective method with these pockets. The corporate is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of extremely selective small molecule therapeutics concentrating on excessive worth, historically undruggable targets in oncology and immunology. For extra info, please go to www.vividion.com.